Abstracts tagged "Infection"

Abstract Number: 0259 • ACR Convergence 2024
Whipple’s Disease in Patients Initially Diagnosed with Rheumatic Diseases: A Case Series
Judith den Hertog¹, Maike Wientjes¹, Jaap ten Oever², Merel Opdam¹, Denise Telgt¹ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Radboudumc, Nijmegen, Netherlands
Background/Purpose: Whipple’s disease is a presumably rare, chronic infectious disease caused by the bacterium Tropheryma whipplei. Symptoms include weight loss, diarrhea, abdominal discomfort, joint pain…
Abstract Number: 0984 • ACR Convergence 2024
Predicting Risk of Infection in Hospitalized Patients with Rheumatic Diseases from the MIMIC-IV Clinical Database: A Machine Learning Approach
Mario Felix¹ and Lais Osmani², ¹Yale, Hamden, CT, ²Yale, New Haven, CT
Background/Purpose: Rheumatic diseases often require immunosuppressive treatment, increasing the risk of infection. Clinicians frequently face challenges distinguishing between infection and disease flare in these patients,…
Abstract Number: 1938 • ACR Convergence 2024
Evaluating Diagnostic Performance of Mycobacterium Tuberculosis Derived Cell-free DNA (CF-DNA) for Diagnosis of Osteoarticular Tuberculosis (OATB): A Novel Method
Kusum Sharma¹, Aman Sharma², Mandeep Singh Dhillon³ and Salony Verma⁴, ¹PGIMER, Chandigarh, Chandigarh, India, ²PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ³Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, Chandigarh, India, ⁴Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India
Background/Purpose: Diagnostic delay not only worsens the outcomes of tuberculosis but also important impediments to TB elimination efforts. The DNA present in cell-free form is…
Abstract Number: 0138 • ACR Convergence 2024
SARS-CoV-2 Vaccine Acceptance, Hesitancy and Uptake in a Cohort of Patients with Inflammatory Rheumatic Diseases (IRD)
iulia roman¹, Xenofon Baraliakos², Uta Kiltz³, Juergen Braun⁴ and Ioana Andreica⁵, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Vaccine acceptance is important to achieve high vaccination coverage and possibly herd immunity. Related to the evolution of the SARS-CoV-2 pandemic with its socio-political…
Abstract Number: 0260 • ACR Convergence 2024
National Survey on Patient’s Knowledge and Drivers of Human Papillomavirus (HPV) Vaccination in Immune-mediated Inflammatory Diseases (IMIDs)
Tiphaine Goulenok¹, Arthur Mageau², Chrystelle Francois¹, Eric HACHULLA³, Thomas Papo² and Karim Sacré², ¹Assistance Publique Hôpitaux de Paris, Paris, France, ²Université Paris Cité, Paris, France, ³CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., LILLE, France
Background/Purpose: Persistent human papillomavirus (HPV) infection is the cause of cervical cancer. Patients with immune-mediated inflammatory diseases (IMIDs) exposed to immunosuppressive therapy are at increased risk…
Abstract Number: 0990 • ACR Convergence 2024
Predictors of Adverse Events and Complications in Cirrhotic Patients with Rheumatoid Arthritis: A Nationwide Analysis
Nidaa Rasheed¹, Humzah Iqbal² and Candice Reyes³, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³VACCHCS, Fresno, CA
Background/Purpose: Cirrhosis is associated with a host of complications such as coagulopathy, renal impairment, esophageal varices, peritonitis, and increased mortality. Rheumatoid arthritis (RA) is a…
Abstract Number: 2209 • ACR Convergence 2024
Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis
Michael George¹, Kelly Gavigan², Shilpa Venkatachalam³, David Curtis², Laura Stradford⁴, William Benjamin Nowell⁵, Joshua Baker¹, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Regeneron, New York, NY, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Serious infections are a major cause of morbidity and mortality in patients with RA, but less is known about more common, non-serious infections. We…
Abstract Number: 0218 • ACR Convergence 2023
Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases
Yumeko Kawano¹, Xiaosong Wang¹, Naomi Patel², Grace Qian¹, Emily Kowalski¹, Katarina Bade³, Kathleen Vanni¹, Accelerating Medicines Partnership (AMP): RA/SLE¹, Zachary Williams², Claire Cook², Shruthi Srivatsan², Zachary Wallace⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: During the height of the COVID-19 pandemic in the United States, tixagevimab/cilgavimab (Evusheld), a combination of monoclonal antibodies directed against the SARS-CoV2 spike protein,…
Abstract Number: 0983 • ACR Convergence 2023
Association Between Disease-modifying Anti-rheumatic Drugs and Short-term Outcomes of Dengue: A Population-based, Cohort Study
I-Feng Lin¹, Hsin-Hua Chen², Theodore Tsai³ and Nicole Huang⁴, ¹National Yang Ming Chiao Tung University, Taipei, Taiwan, ²Taichung Veterans General Hospital, Taichung, Taiwan, ³Takeda Vaccines, Cambridge, MA, ⁴Master of Public Health Program, National Yang Ming Chiao Tung University, Taipei, Taiwan
Background/Purpose: Dengue is the leading vectorborne disease globally with half of the global population at risk, including Puerto Rico in the United States. Previously, we…
Abstract Number: 1669 • ACR Convergence 2023
High Incidence of Immune-mediated Inflammatory Diseases in Sepsis Survivors: A Nationwide Exposed-non-exposed Epidemiological Study
Arthur Mageau¹, Alois Helary², Stephane Ruckly³, Andrey Strukov², Thomas Papo¹, Jean-Francois Timsit¹ and Karim Sacre¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hopitaux de Paris, Paris, France, ³INSERM, Paris, France
Background/Purpose: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Previous studies have shown that immune dysregulation associated with severe…
Abstract Number: 2281 • ACR Convergence 2023
Epidemiology and Risk of Brain Abscess in Patients with Systemic Lupus Erythematosus in Taiwan: A Nationwide Population-based Study
Ke-Hung Lin¹, Tzu-Min Lin¹ and Chi-Ching Chang², ¹Taipei Medical University Hospital, Taipei, Taiwan, ²Taipei Medical University, Taipei, Taiwan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune systemic disorder with high morbidity and mortality. Although CNS infections account for only 0.53–2.25% of all infections…
Abstract Number: 0014 • ACR Convergence 2023
The 330 Genetic Risk Loci of Systemic Lupus Erythematosus (SLE) Now Known Are Consonant with Multiple Causal Mechanisms Involving Epstein-Barr Virus (EBV)-Encoded Transcription Co-factors (TFs) in EBV-Infected B Cells
Viktoryia Laurynenka¹, Xiaoting Chen², sreeja Parameswaran², Leah Kottyan², Matthew Weirauch², Iouri Chepelev³, Kenneth Kaufman³ and John Harley³, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: Association of EBV infection with SLE, data suggesting an anti-EBNA1 molecular mimicry fostering SLE autoimmunity, and mechanisms in EBV infected B cells support a…
Abstract Number: 0224 • ACR Convergence 2023
Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study
Emily Kowalski¹, Xiaosong Wang¹, Naomi Patel², Yumeko Kawano¹, Claire Cook², Kathleen Vanni¹, Grace Qian¹, Katarina Bade³, Shruthi Srivatsan², Zachary Williams², Zachary Wallace⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: As initial COVID-19 infections become nearly ubiquitous and the available prevention and treatment strategies evolve, patients with systemic autoimmune rheumatic diseases (SARDs) may be…
Abstract Number: 0990 • ACR Convergence 2023
Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry
Kelly Gavigan¹, Esteban Rivera², Odette Kolenky³, Cassie Clinton⁴, Emily Holladay⁴, David Curtis⁵, Laura Stradford⁶, Jeffrey Curtis⁴, W. Benjamin Nowell⁶, Christian Curtis⁷ and Michael George⁸, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, Long Island City, NY, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Global Healthy Living Foundation, San Francisco, CA, ⁶Global Healthy Living Foundation, Nyack, NY, ⁷Illumination Health, Birmingham, AL, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Infections are a major contributor to morbidity and mortality in patients (pts) with rheumatoid arthritis (RA). Little is known about the risk of non-serious…
Abstract Number: 1670 • ACR Convergence 2023
Exacerbation of Immune-mediated Inflammatory Diseases in COVID19 Sequelae
CAMILA CAETANO¹, Tamiris Azamor¹, Nikki M. Meyer¹, Cassandra Calabrese², Leonard Calabrese², Nicolas Piuzzi³, M. Elaine Husni², Suan-Sin Foo¹ and Weiqiang Chen¹, ¹Cleveland Clinic / Infection Biology Program, Global Center for Pathogen Research and Human Health, Lerner Research Institute, Cleveland, OH, ²Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ³Cleveland Clinic / Department of Orthopedic Surgery, Cleveland, OH
Background/Purpose: Patients with underlying immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), have a higher susceptibility to severe COVID19…

« Previous Page
1
…
6
7
8
9
10
…
36
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].